Miano Deanna Ingrassia, Cosgrove Ryan, Sherman Joshua, Balaraman Savitha, Sherman Michael
Department of Ophthalmology, Ascension Eye Institute - Ascension Macomb-Oakland Hospital, Warren, Michigan, USA.
Department of Neurology and Ophthalmology, Michigan State University, East Lansing, Michigan, USA.
Neuroophthalmology. 2022 Sep 7;47(2):93-99. doi: 10.1080/01658107.2022.2108847. eCollection 2023.
A 65-year-old male presented to the Ophthalmology clinic with painless loss of vision in his right eye. Over the previous week the right eye's vision had progressed from being blurry to complete loss. Three weeks prior to presentation he had begun treatment with pembrolizumab for urothelial carcinoma. Ophthalmological assessment and subsequent imaging prompted further investigation, and a temporal artery biopsy confirmed a diagnosis of giant cell arteritis. This case demonstrates a rare, yet serious, condition of biopsy-confirmed giant cell arteritis in the setting of pembrolizumab treatment for urothelial carcinoma. In addition to reporting a vision threatening side effect of pembrolizumab we emphasise the need for vigilant care of patients on this drug as symptomatology and laboratory results may be inconspicuous.
一名65岁男性因右眼无痛性视力丧失就诊于眼科门诊。在之前的一周里,右眼视力从模糊发展到完全丧失。就诊前三周,他开始使用派姆单抗治疗尿路上皮癌。眼科评估及后续影像学检查促使进一步调查,颞动脉活检确诊为巨细胞动脉炎。该病例显示了在使用派姆单抗治疗尿路上皮癌的情况下,经活检确诊的巨细胞动脉炎这一罕见但严重的病症。除了报告派姆单抗的视力威胁性副作用外,我们强调对使用该药物的患者需要进行密切监测,因为症状和实验室检查结果可能不明显。